USTR to “clarify” its position on extension of LDC transition period for TRIPS
On June 11, 2011, KEI published KEI Policy Brief 2011:1, which was titled: “White House and European Commission trade official oppose waiver of drug patents for Least Developed Countries (LDCs).”